• Tuberculosis

Capastat Generic Name & Formulations

General Description

Capreomycin (as sulfate) 1g/vial; pwd for IV infusion after reconstitution and dilution, or IM inj after reconstitution.

Pharmacological Class


How Supplied

Vial (10mL)—1


Mechanism of Action

Capreomycin, a polypeptide antibiotic, is active against strains of Mycobacterium tuberculosis found in humans.

Capastat Indications


Adjunct in susceptible tuberculosis when first-line agents (INH, rifampin, ethambutol, aminosalicylic acid, streptomycin) are inappropriate.

Capastat Dosage and Administration


Give by IV infusion over 1 hour or deep IM inj. 1g (max 20mg/kg) daily for 60–120 days, then 1g (max 20mg/kg) 2–3 times per week; max 20mg/kg per day. Treat for 12–24 months. Renal dysfunction: reduce dose (see full labeling).


Not established.

Capastat Contraindications

Not Applicable

Capastat Boxed Warnings

Boxed Warning

May be associated with worse clinical outcomes (eg, decreased effectiveness, increased mortality) compared with other parenteral therapy for pulmonary MDR-TB. Use with extreme caution in patients with renal insufficiency or preexisting auditory impairment. 

Capastat Warnings/Precautions


See Boxed warning. Should reserve for those with resistance to injectable aminoglycosides and limited treatment options. Renal or auditory impairment. Risk for additional cranial nerve VIII impairment or renal injury. Assess audiometric measurements and vestibular function prior to initiation and at regular intervals during therapy. Monitor renal function at baseline and weekly during therapy; reduce dose or discontinue if BUN>30mg/dL or if renal function decreases. Monitor hepatic function and serum potassium, magnesium, and calcium levels. Elderly. Pregnancy: may be teratogenic. Nursing mothers.

Capastat Pharmacokinetics



Capastat Interactions


Concomitant streptomycin, other parenteral antituberculars: not recommended. Increased toxicity with other neuro/ototoxic drugs (eg, aminoglycosides); use cautiously.

Capastat Adverse Reactions

Adverse Reactions

Neurotoxicity (esp. ototoxicity), renal toxicity, leukocytosis, leukopenia, abnormal liver function tests, inj site reactions (eg, pain, induration, bleeding), rash.

Capastat Clinical Trials

See Literature

Capastat Note

Not Applicable

Capastat Patient Counseling

See Literature